ArticleResearch and practice in thrombosis and haemostasis2020
Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome.
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis.Blood advances · 2021Pooled it
- Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021Pooled it
- Longer Prehospitalization and Preintubation Periods in Intubated Non-survivors and ECMO Patients With COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis.Critical care (London, England) · 2020Pooled it
- A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease.Pharmaceuticals (Basel, Switzerland) · 2023Review
- High-Dose Prophylactic Anticoagulation for COVID-19 Pneumonia: A Review of Benefits and Risks.Cureus · 2023Review
- Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination.Trends in cardiovascular medicine · 2022Review
- Accelerated heparin-induced thrombocytopenia in a COVID-19 patient; a case report with literature review.Annals of medicine and surgery (2012) · 2022Article
- Ischemic Stroke and Bilateral Pulmonary Embolism in COVID-19: COVID-Associated Coagulopathy or Heparin-Induced Thrombocytopenia.Journal of hematology · 2022Article
- COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Hypercoagulopathy in Overweight and Obese COVID-19 Patients: a Single-Center Case Series.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2022Article
- The roles of serotonin in cell adhesion and migration, and cytoskeletal remodeling.Cell adhesion & migration · 2021Review
- Autoimmunity roots of the thrombotic events after COVID-19 vaccination.Autoimmunity reviews · 2021Review
- The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19.International journal of laboratory hematology · 2021Review
- [SARS-CoV-2 vaccines induced immune thrombotic thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Perspectives on vaccine induced thrombotic thrombocytopenia.Journal of autoimmunity · 2021Review
- Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity.PLoS medicine · 2021Review
- COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.Journal of thrombosis and haemostasis : JTH · 2021Article
- COVID-19 and Cardiovascular Disease: From Bench to Bedside.Circulation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early reports of coronavirus disease 2019 (COVID-19) clinical features describe a hypercoagulable state, and recent guidelines recommend prophylactic anticoagulation for patients with COVID-19 with low-molecular-weight heparin, but this would be contraindicated in the presence of heparin-induced thrombocytopenia (HIT). We address the key clinical question whether HIT is also present during COVID-19. We report 3 cases of thrombocytopenia with antiplatelet factor 4 antibodies among 16 intubated patients with COVID-19 with adult respiratory distress syndrome, a higher-than-expected incidence of 19%. Each patient had evidence of thrombosis (pulmonary embolism, upper extremity venous thromboses, and skin necrosis, respectively). The serotonin release assay confirmed HIT in 1 case, and 2 cases were negative. We believe this is the first reported case of HIT during the COVID-19 pandemic. Recognition that the thrombocytopenia represented HIT in the confirmed case was delayed. We recommend clinicians monitor platelet counts closely during heparin therapy, with a low threshold to evaluate for HIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.